Key opinion leaders describe when to refer a patient with lymphoma and at what point treatments should be switched, and the evolution of T-cell engaging therapies.
Zanubrutinib Combo Improves ORR Vs Obinutuzumab in Follicular Lymphoma
October 24th 2023The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.